GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (LTS:0MTD) » Definitions » Debt-to-EBITDA

Swedish Orphan Biovitrum AB (LTS:0MTD) Debt-to-EBITDA : 2.16 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Swedish Orphan Biovitrum AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr7,645 Mil. Swedish Orphan Biovitrum AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr11,575 Mil. Swedish Orphan Biovitrum AB's annualized EBITDA for the quarter that ended in Mar. 2024 was kr8,888 Mil. Swedish Orphan Biovitrum AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 2.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Debt-to-EBITDA or its related term are showing as below:

LTS:0MTD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0   Med: 2.04   Max: 5.29
Current: 2.63

During the past 13 years, the highest Debt-to-EBITDA Ratio of Swedish Orphan Biovitrum AB was 5.29. The lowest was 0.00. And the median was 2.04.

LTS:0MTD's Debt-to-EBITDA is ranked worse than
62.5% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.675 vs LTS:0MTD: 2.63

Swedish Orphan Biovitrum AB Debt-to-EBITDA Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Debt-to-EBITDA Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.73 2.18 1.91 1.50 2.83

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 6.70 3.55 2.02 2.16

Competitive Comparison of Swedish Orphan Biovitrum AB's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Debt-to-EBITDA falls into.



Swedish Orphan Biovitrum AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Swedish Orphan Biovitrum AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8961 + 11524) / 7234
=2.83

Swedish Orphan Biovitrum AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(7645 + 11575) / 8888
=2.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Swedish Orphan Biovitrum AB  (LTS:0MTD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Swedish Orphan Biovitrum AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (LTS:0MTD) Business Description

Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (LTS:0MTD) Headlines

No Headlines